Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

Emily and Joey Spadafore watched helplessly as their 3-month-old son, Benjamin, battled RSV for a week in the hospital.

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free ...

A new immunization for respiratory syncytial virus (RSV) is proving highly effective in preventing severe cases in infants.

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Feb. 19, 2025 – A vaccine for pregnant women that protects babies from respiratory syncytial virus (RSV) appears safe, according to two new studies that give researchers hope for widespread ...